Urogen Pharma (URGN) News Today $18.06 -0.73 (-3.89%) Closing price 04:00 PM EasternExtended Trading$18.79 +0.73 (+4.04%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Urogen Pharma (NASDAQ:URGN) Raised to Hold at Wall Street ZenSeptember 15 at 2:07 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Upgraded by Wall Street Zen to "Hold" RatingSeptember 14 at 3:55 AM | americanbankingnews.comTrexquant Investment LP Sells 157,097 Shares of Urogen Pharma $URGNSeptember 13 at 3:11 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 8% on Insider SellingSeptember 12 at 11:11 AM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 SharesSeptember 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 SharesSeptember 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Should You Buy?September 11, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider SellingSeptember 11, 2025 | americanbankingnews.comUrogen Pharma (NASDAQ:URGN) Shares Up 10.6% - What's Next?September 10, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in StockSeptember 10, 2025 | insidertrades.comUroGen Pharma announces inducement grants under Nasdaq listing ruleSeptember 9, 2025 | msn.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 8, 2025 | globenewswire.comUrogen Pharma $URGN Holdings Boosted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comUrogen Pharma $URGN Stock Position Decreased by Adage Capital Partners GP L.L.C.September 8, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Rating of "Buy" from AnalystsSeptember 8, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Buy" by AnalystsSeptember 7, 2025 | americanbankingnews.comVestal Point Capital LP Boosts Position in Urogen Pharma $URGNSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Acquires Shares of 3,206,271 Urogen Pharma $URGNSeptember 4, 2025 | marketbeat.comNuveen LLC Invests $1.03 Million in Urogen Pharma $URGNSeptember 3, 2025 | marketbeat.comPartners Capital Investment Group LLP Invests $170,000 in Urogen Pharma $URGNAugust 24, 2025 | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesAugust 21, 2025 | globenewswire.comFox Run Management L.L.C. Takes Position in Urogen Pharma $URGNAugust 21, 2025 | marketbeat.comPiper Sandler Initiates Coverage of UroGen Pharma (URGN) with Overweight RecommendationAugust 20, 2025 | msn.comPiper starts ‘underestimated’ UroGen Pharma with an OverweightAugust 19, 2025 | msn.comUroGen Pharma initiated with an Overweight at Piper SandlerAugust 18, 2025 | msn.comUroGen Pharma: Targeting Profits In 2027August 18, 2025 | seekingalpha.comOak Ridge Investments LLC Has $815,000 Position in Urogen Pharma (NASDAQ:URGN)August 17, 2025 | marketbeat.comQ3 EPS Estimates for Urogen Pharma Reduced by HC WainwrightAugust 16, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 10,000 SharesAugust 15, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 14, 2025 | marketbeat.com17,571 Shares in Urogen Pharma (NASDAQ:URGN) Acquired by Persistent Asset Partners LtdAugust 13, 2025 | marketbeat.comUroGen Pharma’s Earnings Call: Achievements and ChallengesAugust 13, 2025 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for Urogen Pharma (NASDAQ:URGN) Stock PriceAugust 12, 2025 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Releases Earnings Results, Misses Expectations By $0.20 EPSAugust 11, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their EstimatesAugust 10, 2025 | finance.yahoo.comUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comUroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call PresentationAugust 9, 2025 | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Stock Price Down 14.4% Following Weak EarningsAugust 8, 2025 | marketbeat.comUroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...August 8, 2025 | finance.yahoo.comUroGen Pharma Reports Q2 2025 Results and Launches ZUSDURIAugust 8, 2025 | tipranks.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7, 2025 | investing.comUroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beatAugust 7, 2025 | investing.comUrogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara BancroftAugust 7, 2025 | tipranks.comUroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comUroGen Pharma Q2 2025 Earnings PreviewAugust 6, 2025 | msn.comD. Boral Capital Reaffirms Buy Rating for Urogen Pharma (NASDAQ:URGN)August 6, 2025 | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade ...August 6, 2025 | finance.yahoo.comUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High - Should You Buy?August 5, 2025 | marketbeat.comUroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerAugust 5, 2025 | globenewswire.com Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Videos URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.840.94▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼1412▲URGN Articles Average Week Get the Latest News and Ratings for URGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Urogen Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Akero Therapeutics News Today Zai Lab News Today Apellis Pharmaceuticals News Today Scholar Rock News Today Crinetics Pharmaceuticals News Today Telix Pharmaceuticals News Today Viking Therapeutics News Today Ultragenyx Pharmaceutical News Today Amneal Pharmaceuticals News Today Kymera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts